Scilex Holding (SCLX) Change in Account Payables (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Account Payables of $15.8 million for Q1 2026, up 208.35% year-over-year from $5.1 million in Q1 2025, and up 794.34% on a QoQ basis from $1.8 million in Q4 2025.
Scilex Holding (SCLX) Change in Account Payables (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Change in Account Payables for 5 consecutive years, with $15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 208.35% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $23.8 million (up 111.0% YoY), while the FY2025 annual figure was $13.1 million, up 76.86% from the prior year.
- Change in Account Payables came in at $15.8 million for Q1 2026 at Scilex Holding, up from $1.8 million in the prior quarter.
- The five-year high for Change in Account Payables was $15.8 million in Q1 2026, with the low at -$612000.0 in Q2 2024.
- Average Change in Account Payables over 5 years is $3.5 million, with a median of $2.0 million recorded in 2023.
- Across the five-year window, Change in Account Payables surged 5313.66% in 2023 and slumped 126.23% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at -$161000.0 in 2022, then soared by 5313.66% to $8.4 million in 2023, then sank by 38.61% to $5.2 million in 2024, then slumped by 65.69% to $1.8 million in 2025, then soared by 794.34% to $15.8 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $15.8 million, $1.8 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 15.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.81 Mn |
| Mar 31, 2026 | 15.81 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | -612,000.00 |
| Jun 30, 2024 | -612,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 8.39 Mn |
| Dec 31, 2023 | 8.39 Mn |